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Recent pandemic planning has highlighted the importance of understanding the effect that widespread
antiviral use will have on the emergence and spread of resistance. A number of recent studies have deter-
mined that if resistance to antiviral medication can evolve, then deploying treatment at a less than
maximum rate often minimizes the outbreak size. This ﬁnding, however, involves the assumption that
treatment levels remain constant during the entire outbreak. Using optimal control theory, we address
the question of optimal antiviral use by considering a large class of time-varying treatment strategies.
We prove that, contrary to previous results, it is always optimal to treat at the maximum rate provided
that this treatment occurs at the right time. In general the optimal strategy is to wait some ﬁxed
amount of time and then to deploy treatment at the maximum rate for the remainder of the outbreak.
We derive analytical conditions that characterize this optimal amount of delay. Our results show that it
is optimal to start treatment immediately when one of the following conditions holds: (i) immediate treat-
ment can prevent an outbreak, (ii) the initial pool of susceptibles is small, or (iii) when the maximum
possible rate of treatment is low, such that there is little de novo emergence of resistant strains. Finally,
we use numerical simulations to verify that the results also hold under more general conditions.
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1. INTRODUCTION
The current interest in inﬂuenza pandemics has empha-
sized the importance of understanding the implications
of drug resistance for different types of public health
interventions. Recent studies have considered the conse-
quences of drug resistance on the effectiveness of
several intervention strategies, including drug prophylaxis
and treatment, vaccination, non-drug interventions, as
well as combinations of interventions and multi-drug
therapy [1–17]. Many of these studies have revealed
interesting and unexpected behaviour. In particular,
numerous studies have now demonstrated that, with
respect to drug treatments, there is sometimes an inter-
mediate optimal level of treatment that minimizes the
total outbreak size [8,9,12–14].
This result is somewhat counterintuitive, and arises
from a trade-off between the costs and beneﬁts of treating
infected individuals. In fact, treatment has three effects on
the total outbreak size: (i) treatment is beneﬁcial because
it suppresses the spread of the sensitive strain, (ii) treat-
ment is costly because it leads to the de novo
appearance of resistant infections, and (iii) treatment is
costly because suppression of the sensitive strain frees
up susceptible hosts that can then be infected by the
resistant strain [9]. The treatment level that minimizes
the total outbreak size should thus strike the optimal
balance among these three effects.
These ﬁndings clearly reveal that the prospect of
pathogen evolution during a disease outbreak can have a
signiﬁcant impact on the design of optimal intervention
strategies. Nevertheless, it is important to note that
most of these results make a key implicit assumption;
namely that, whatever treatment level is chosen, it must
remain constant during the entire course of the outbreak.
An interesting exception is the studies by Moghadas et al.
[12,13], where numerical examples are used to illustrate
that an even smaller total outbreak size can sometimes
be obtained by switching from one level of treatment to
another once the outbreak is underway.
Given the above collection of results, it is clear that
the optimal treatment strategy during an outbreak is not
yet completely understood. In this paper, we address
this issue through the use of optimal control theory
[18–21]. In particular, we consider a model in which
we allow for arbitrary, time-varying, treatment strategies
during an outbreak, and we derive analytical expressions
that characterize the form of the optimal strategy. We
prove that, contrary to the implications of previous
studies, it is always optimal to use maximum treatment
levels provided that this treatment occurs at the right time.
In general, the optimal strategy is to wait some ﬁxed
period of time once the outbreak has begun, and then
to deploy treatment at a maximum level. We show that
the optimal delay is one that balances the above-men-
tioned costs and beneﬁts. Finally, we explore extensions
of the model to more complex scenarios in order to
illustrate the robustness of our conclusions.
2. MATHEMATICAL MODEL
The model, depicted in ﬁgure 1a, describes the basic
transmission dynamics of an infectious disease and
includes the effects of treatment, as well as the presence
of a strain resistant to treatment. An individual can be
susceptible (S), infected with a sensitive strain (I),
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with a resistant strain (R). Susceptible individuals become
infected with the sensitive strain through contact with
individuals in the I and T compartments (with contact
parameters bI and bT, respectively), and become infected
with the resistant strain through contact with individuals
in the R compartment (with contact parameter bR). Indi-
viduals infected with the sensitive strain can move into the
treated class at some (time-varying) per capita rate, u(t),
where u is the treatment strategy of interest. Treated indi-
viduals can develop resistance at some constant per capita
rate, n, and ﬁnally, individuals in each of the three
infected classes can leave the system, through either
death or recovery with immunity, at constant per capita
rates mI, mT and mR (also see electronic supplementary
material, §1).
The objective of the analysis is to determine the opti-
mal time-varying treatment strategy, u, that minimizes
the total attack ratio (i.e. minimizes the attack ratio of
the sensitive strain plus the attack ratio of the resistant
strain), given by
A ¼
Sðt0Þ SðtfÞ
Sðt0Þ
;
which is equivalent to minimizing the total outbreak size
(and to maximizing the ﬁnal number of susceptibles).
The quantities t0 and tf are the start and end times of
the outbreak, respectively. We say that the outbreak has
ended as soon as the total number of all disease-transmit-
ting individuals is equal to 1. In other words, for the
model depicted in ﬁgure 1a, tf ¼ minftj I(t) þ T(t) þ
R(t)   1g. By deﬁning tf in this way, we avoid the situation
where an unrealistically small number of infecteds
(namely less than one infected) initiates an outbreak.
The rational for this deﬁnition of tf is further detailed in
electronic supplementary material, §2 and in Hansen &
Day [22].
The treatment level, u, can vary through time, and can
take on any value from 0 to some maximum value, umax.
The upper bound, umax, reﬂects the fact that, regardless of
how much we strive to increase the rate of treatment, it
will typically be unavoidable that infected individuals
spend some amount of time circulating in the population
before they are treated. This will occur because of con-
straints on treatment delivery (e.g. having a ﬁnite
number of health professionals available to deliver
treatment), as well as constraints imposed by the biology
of the disease (e.g. if there is an asymptomatic stage).
The above model is qualitatively similar to those exam-
ined by Handel et al. [8], Lipsitch et al. [9], Moghadas
et al. [13] and Qiu & Feng [14], but we make a further
pair of simplifying assumptions to facilitate mathematical
analysis: (i) that treatment is perfectly effective, meaning
that essentially no transmission occurs from treated
individuals, and (ii) that the time dynamics of the treated
class are fast relative to those of the other classes. In this
case, we can use the quasi-equilibrium value of T to sim-
plify the model (electronic supplementary material, §1).
This simpliﬁcation removes the highlighted elements of
the ﬂow diagram in ﬁgure 1a, and yields the following
equations:
_ S ¼  bIIS   bRRS;
_ I ¼ bIIS  ð mI þ uÞI
_ R ¼ bRRS   mRR þ kuI;
9
> > > =
> > > ;
; ð2:1Þ
where k denotes the probability that a treated individual
develops resistance.
Although the above simplifying assumptions might not
be particularly realistic for some situations, our primary
aim is to develop a broad conceptual understanding of
the optimal treatment strategy during an outbreak. More-
over, these assumptions do not appear to qualitatively
alter the results, as evidenced by the numerical simu-
lations presented later. In fact, these simpliﬁcations
primarily accentuate the three key effects of treatment
that were discussed in §1. First, model (2.1) assumes
that treatment completely suppresses the spread of the
sensitive strain and therefore it maximizes the ﬁrst effect
of treatment (i.e. the suppression of sensitive infections).
Second, model (2.1) assumes that, if de novo resistance
appears at all, it arises immediately upon treatment
because the dynamics of the treated class are assumed
to be fast relative to the other classes. Third, model
(2.1) also removes the impact of treated individuals on
the depletion of susceptible hosts, therefore maximizing
the third effect of treatment (i.e. the freeing-up of
susceptible hosts for infection by resistant strains).
3. RESULTS
To facilitate the understanding of our results, we ﬁrst
deﬁne some important quantities and brieﬂy describe
(a)( b)
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 RS
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Figure 1. Model structure. (a) Schematic for the treatment model that is used to motivate model (2.1). An individual can be
susceptible (S), infected with a sensitive strain (I), infected with a sensitive strain and treated (T) or infected with a resistant
strain (R). The dynamics of the treated class have been enclosed in dashed boxes to emphasize the difference between this
ﬁgure and the equations for model (2.1). All analytic results are derived using model (2.1), which does not include the
dynamics of the treated class. (b) Schematic for the detailed model. Using numerical simulations, the analytic results for
model (2.1) have been extended to this more detailed model that includes the dynamics of the treated class.
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egy. We then give a complete characterization of the
optimal treatment strategy in two steps. First, we consider
a special case (situation 1) in which we can use standard
techniques from calculus to gain an intuition for the
results. Second, we characterize the optimal treatment
strategy in general (situation 2). Analysis of the latter
case requires techniques from optimal control theory,
and these details are presented in the electronic
supplementary material.
The optimal treatment strategy for model (2.1) is
characterized by the following three quantities:
RI ¼
bI
mI
Sðt0Þ¼
Sðt0Þ
SI
; ðiÞ
RR ¼
bR
mR
Sðt0Þ¼
Sðt0Þ
SR
; and ðiiÞ
RIR ¼
bI
mI þ umax
þ
bR
mR
kumax
mI þ umax
  
Sðt0Þ: ðiiiÞ
Here, RI and RR are the basic reproduction numbers of
the sensitive and resistant strain, respectively [23–25].
The quantities SI ¼ mI/bI and SR ¼ mR/bR represent
threshold parameters, and denote the number of suscep-
tibles above which a sensitive and resistant outbreak can
occur, respectively. To understand the constant RIR, con-
sider the possible paths that a new sensitive infection can
take. If the population is receiving treatment (i.e. u = 0),
then an initially sensitive infection may develop resistance
and so some initially sensitive infections will generate
both sensitive and resistant infections during their life-
time. The constant RIR can be interpreted as the total
expected number of secondary infections (both sensitive
and resistant) caused by an individual initially infected
with the sensitive strain in a wholly susceptible population
that is receiving maximum treatment (i.e. u ; umax).
Speciﬁcally, the ﬁrst term represents the number of infec-
tions generated while infected with the sensitive strain,
and the second term represents the probability of devel-
oping resistance, multiplied by the number of infections
generated while infected with this newly evolved resistant
strain.
A few more general observations will be helpful before
stating the results. First, RIR can be expressed as RIR ¼ RI
(1 2 x) þ xkRR, where x ¼ umax/(mI þ umax) is the pro-
bability of an infected individual receiving treatment
when the treatment effort is u ; umax. This expresses
RIR as a mixture of the two reproduction numbers, RI
and RR. Second, because the number of susceptibles
always decreases through time, it is sometimes easier to
express the optimal treatment strategy as a function of
the size of the susceptible pool rather than as a function
of time per se. This is also more useful from a health
policy point of view because ‘number of susceptibles’ is
a much more meaningful (and more easily measured)
quantity than ‘time since start of outbreak’. Thus,
although in the sequel we will discuss ‘treatment start
time’ and ‘delay’, these will sometimes be measured in
terms of the corresponding number of susceptible indi-
viduals. For reference all symbols have been deﬁned in
table 1.
(a) The optimal treatment strategy
The optimal treatment strategy is to delay treatment until some
ﬁxed time t* (possibly t* ¼ t0) and then to treat maximally
for the remainder of the epidemic. Thus, higher treatment
levels are always better provided that the onset of
treatment is delayed by the optimal amount.
(b) The optimal amount of delay
To simplify the conditions for the optimal delay, suppose
that RI   RR (the resistant strain suffers a ﬁtness cost in
the absence of treatment) and k , 1 (not all treated infec-
tions develop resistance; the complete analysis is
presented in the electronic supplementary material). In
this case, the optimal delay can be characterized in
terms of a critical number of susceptible hosts, deﬁned by
Smin ¼ SR þ
k
1   k
ðSR   SIÞ:
The optimal delay is achieved by balancing the effect
that delay has on the sensitive and resistant outbreaks,
and this is best understood by considering two separate
situations: (1) the maximum treatment level is very
large (umax ! 1) and (2) the maximum treatment level
is not very large (umax is ﬁnite).
Situation 1. If the maximum treatment level is very
large, then some insight into the optimal treatment strat-
egy can be gained using basic calculus. In particular, if the
maximum level of treatment is used, then the onset of
treatment effectively ends the sensitive epidemic and
initiates the start of the resistant epidemic. This is because
at the onset of treatment, all sensitive-infected individuals
enter either the removed compartment (i.e. they are trea-
ted and no longer transmitting the infection) or the
resistant compartment (i.e. treatment causes them to
immediately develop resistance). Therefore, before
treatment begins, model (2.1) simpliﬁes to
_ S ¼  bIIS
_ I ¼ bIIS   mII;
)
; ð3:1Þ
with initial conditions (S(t0),I(t0)). Once treatment
begins at time t ¼ t, all of the sensitive-infected individ-
uals either (i) immediately become resistant or
(ii) immediately stop transmitting the infection. Thus,
for t . t, model (2.1) simpliﬁes to
_ S ¼  bRRS
_ R ¼ bRRS   mRR;
)
; ð3:2Þ
with (S(t),R(t)) ¼ (S(t),kI(t)). Hence, in this special
case, determining the optimal treatment strategy amounts
to determining the optimal time to switch from model
(3.1) to model (3.2).
Integrating and rearranging the equations for model
(3.1) and model (3.2) give (see electronic supplementary
material, §3, for details):
SRlnSðtfÞ SðtfÞ¼ð1 kÞðSminlnSðtÞ SðtÞÞþC;
ð3:3Þ
where C ¼ k(SI lnS(t0) 2 S(t0) 2 I(t0)) þ R(tf). Now since,
by deﬁnition, the outbreak ends as soon as the total number
of infecteds is less than or equal to 1, there are two
possibilities with respect to the optimal delay.
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kI(t0) , 1, then starting treatment at t0 prevents the out-
break (i.e. R(t) ¼ kI(t) , 1). Clearly, this is the best
possible scenario, and therefore t* ¼ t0. Notice that this
situation is closely related to the idea of ‘containment’
discussed in Lipsitch et al. [9].
(B) Treating immediately cannot prevent the outbreak:i f
the outbreak cannot be prevented through treatment,
then any treatment strategy will result in S(tf)   SR (i.e.
the outbreak will not end until the pool of susceptibles
is diminished below that necessary to sustain an resistant
outbreak). Therefore, the treatment start time that maxi-
mizes the left-hand side of equation (3.3) will also
maximize S(tf) (and hence minimize the total attack
ratio). In other words, it is optimal to delay treatment
until the number of susceptible hosts has declined to
Sðt*Þ¼Smin:
If the initial number of susceptible hosts is smaller than
this threshold, then treatment should begin immediately.
Situation 2. If the maximum treatment level is
bounded, then there will be some temporal overlap in
the sensitive and resistant epidemics once treatment has
been initiated. In this situation, Pontryagin’s maximum
principle can be used to determine the optimal (time-
varying) treatment strategy (see electronic supplementary
material, §4, for details). There are, again, two
possibilities with respect to the optimal delay.
(A0) Treating immediately can prevent the outbreak:i f
starting treatment at t0 prevents the outbreak from occur-
ring, then this is clearly the best possible scenario, and so
t* ¼ t0. As with situation 1, this situation is closely related
to the idea of ‘containment’discussed in Lipsitch et al. [9]
and is contingent on how tf is deﬁned (i.e. for model (2.1)
we have that tf ¼ minftjI(t) þ R(t)   1g).
(B0) Treating immediately cannot prevent the outbreak:i f
scenario (A0) does not hold, then it may be optimal to
delay the onset of treatment. In particular, the threshold
number of susceptibles Smin now provides an upper
bound on the optimal delay. Thus, if the initial number
of susceptible hosts is smaller than this threshold, then
treatment should begin immediately. On the other hand,
if S(t0) is initially larger than Smin, then the optimal
delay is no larger than the time it takes for the number
of susceptible hosts to decline to Smin. There is one
other possibility, however, that overrides these conditions:
if RIR . RR, then it is optimal to start treatment
immediately.
Note that there are two major differences between the
results for situation 1 and situation 2. First, when maxi-
mum treatment levels are bounded (situation 2), the
critical threshold, Smin, provides only an upper bound
for the optimal delay. Second, in situation 2, there is an
additional condition under which immediate treatment
is optimal; namely, when RIR . RR. Intuitively, if de
novo resistance has a negligible effect on the outbreak,
then it seems reasonable that treatment should proceed
Table 1. Table of symbols.
symbol brief deﬁnition
S(t) number of susceptibles at time t
I(t) number of individuals infected with the treatment-sensitive strain at time t
T(t) number of treated individuals at time t
R(t) number of individuals infected with the treatment-resistant strain at time t
bI contact parameter for the sensitive strain
bT contact parameter for the treated strain (bT ¼ 0 for the simple model)
bR contact parameter for the resistant strain
mI per capita rate of death or recovery with immunity for the sensitive-infected class
mT per capita rate of death or recovery with immunity for the treated class
mR per capita rate of death or recovery with immunity for the resistant-infected class
u(t) per capita rate of treatment for the sensitive-infected class at time t
v per capita rate of developing resistance for the treated class (applies to model in ﬁgure 1a)
k probability that treated individual develops resistance (applies to simple model, see equation (2.1))
t0 the outbreak start time
tf the outbreak end time
umax upper bound for per capita treatment rate u
RI the basic reproduction number for the sensitive strain
RR the basic reproduction number for the resistant strain
RIR the expected number of secondary infections (both sensitive and resistant) caused by an individual initially infected
with the sensitive strain, in a wholly susceptible population that is receiving maximum treatment (i.e. u ; umax)
SI the number of susceptibles above which a sensitive outbreak can occur
SR the number of susceptibles above which a resistant outbreak can occur
x the probability that an infected individual receives treatment (assuming u ; umax)
t an arbitrary treatment start time
t* the optimal treatment start time
fT the fraction of infected individuals that receives treatment (applies to detailed model, see ﬁgure 1b)
Smin the number of susceptibles at the optimal treatment start time assuming that an outbreak occurs and umax is
unbounded (applies to simple model)
Smin,c the number of susceptibles at the optimal treatment start time assuming that an outbreak occurs and fT ¼ 1 (applies
to detailed model)
A the total attack ratio
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that treatment should begin immediately if RIR . RR
actually highlights this intuition and emphasizes that the
quantity that measures the effect of de novo resistance is
the rate of de novo resistance (kuI) and not the prob-
ability of de novo resistance (k). This can be seen by
rearranging RIR . RR and multiplying both sides by kI
to produce a relationship involving the rate of de novo
resistance:
kumaxI ,
k
1   k
mR
bR
 
mI
bI
  
bII: ð3:4Þ
Hence, if the rate of de novo resistance is small, then
treatment should proceed as though there is only a
treatment-sensitive strain (i.e. if equation (3.4) holds
then treatment should start immediately).
(c) Interpretation
We have shown that, for a simple model which includes
the evolution of resistance, the optimal treatment strategy
is to delay treatment for a speciﬁc amount of time (poss-
ibly no time) and then to treat with maximum effort for
the remainder of the epidemic. If an outbreak is unavoid-
able, the optimal amount of delay is determined by
balancing the beneﬁts and costs of delay, and this trade-
off can be best understood by again considering the
case when the maximum treatment level is very large.
When the maximum treatment level is very large (i.e.
situation 1), the marginal change in the attack ratio that
comes from increasing the amount of delay before treat-
ment is (see electronic supplementary material, §3, for
details):
dA
dt
¼
dAI
dt
þ
dAR
dt
; ð3:5Þ
¼
d
dt
Sðt0Þ SðtÞ
Sðt0Þ
  
þ
d
dt
SðtÞ SðtfÞ
Sðt0Þ
  
; ð3:6Þ
¼ a½SR   SðtÞ    ak½SI   SðtÞ ; ð3:7Þ
where A, AI, AR denote the total, sensitive and resistant
attack ratios, respectively, t is the treatment start time
and a ¼ S(tf)bII(t)/[S(t0)(SR 2 S(tf))] . 0.
Equation (3.5) emphasizes that the total attack ratio
can be decomposed into a sensitive attack ratio and a
resistant attack ratio. Furthermore, since for situation 1
the sensitive and resistant outbreaks are temporally separ-
ated (because the resistant strain emerges only after
treatment begins), the sensitive attack ratio includes all
new infections that occur before the treatment start
time t, and the resistant attack ratio includes all new
infections that occur after the treatment start time t
(see equation (3.6)). The two terms in equation (3.7) rep-
resent the beneﬁt and cost of delay, respectively. The ﬁrst
term represents the beneﬁt of a delay that comes from a
reduction in the size of the susceptible pool at the start
of the resistant-strain epidemic. From the perspective of
this beneﬁt term only, it is best to delay treatment until
S(t) ¼ SR, at which point there are no longer enough sus-
ceptible individuals to sustain a resistant outbreak. The
second term represents the cost of delay that comes
from an increase in the number of de novo resistant infec-
tions once treatment begins. From the perspective of this
cost term only, it is best to treat immediately because
waiting longer results in a larger pool of infected individ-
uals, which then have the potential to develop de novo
resistance once treatment begins. The optimal amount
of delay precisely balances these two effects, and this
can be readily interpreted graphically. Figure 2a shows
the ﬁnal number of susceptibles as a function of treatment
start time for different values of k.A sk increases, the
importance of the second term in equation (3.7) increases
and correspondingly the number of infecteds at the opti-
mal treatment start time decreases (ﬁgure 2b), while the
number of susceptibles at the optimal treatment start
time increases (ﬁgure 2c).
(d) Numerical results for more detailed models
Although the analytic expressions presented above are
derived using a simple model, numerical simulations
suggest that these results hold more generally. To illus-
trate this, we use numerical simulations to compare the
relationship between treatment start time and attack
ratio for our simple model and for the more detailed
model in Lipsitch et al. [9]. Figure 1b depicts the treat-
ment model used in Lipsitch et al. [9] and the
corresponding system equations are provided in electronic
supplementary material, §5.
To begin, numerical results show that both models
exhibit two key features: (i) if the treatment level is
constrained to be constant throughout the entire epi-
demic (as has been the case in most previously
published analyses), then there is an intermediate optimal
level of treatment, and (ii) if treatment is delayed by the
appropriate amount, then maximum treatment is always
optimal (electronic supplementary material, ﬁgures 1
and 2). The fact that delaying treatment can be better
than constant treatment in both models explains why
Lipsitch et al. [9], Moghadas et al. [13], Handel et al.
[8] and Qiu & Feng [14] observed an intermediate
optimal constant treatment level.
A comparison of the panels of ﬁgure 3 shows that
the general relationship between the treatment level, the
attack ratio and the number of susceptible hosts at the
start of treatment is qualitatively similar for both
models. Furthermore, ﬁgure 3a shows that for the
simple model, if an outbreak occurs, then S(t*)
approaches Smin as the treatment level increases (i.e. the
solid curve approaches the horizontal dashed line). In
other words, the optimal solution for the case when
umax is very large provides a bound for the case when
umax is ﬁnite. A similar statement is true for the more
detailed model. In the more detailed model, fT denotes
the fraction of infections that are treated, and so fT ¼ 1
is the analogous case to umax being unbounded (i.e. all
infected individuals are treated). Using Smin,c to denote
the number of susceptibles at the optimal treatment
start time when fT ¼ 1, ﬁgure 3c shows that, for the
detailed model, S(t*) decreases as the treatment level
increases, with Smin,c providing a bound for all other
values of fT.
Both models also demonstrate that it is possible to
avoid an outbreak by starting treatment immediately at
sufﬁciently high treatment levels (electronic supplemen-
tary material, ﬁgure 3). Furthermore, if the initial pool
of susceptibles is small enough, then it is always best to
start treatment immediately (electronic supplementary
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is measured relative to the number of susceptibles at the
optimal treatment start time when umax is unbounded.
Namely, if S(t0) , Smin, then t* ¼ t0. Similarly, for the
more detailed model, electronic supplementary material,
ﬁgure 4b, suggests that if S(t0) , Smin,c then again it is
optimal to start treatment immediately.
Finally, recall that for the simple model if RIR . RR,
then it is optimal to start treatment immediately. Using
the biological interpretation of RIR, namely that RIR is
the expected total number of infections caused by an indi-
vidual initially infected with the treatment-sensitive strain,
we can deﬁne an analogous quantity for the detailed
model (see electronic supplementary material, text S1,
for details). Electronic supplementary material, ﬁgures 5
and 6 show that the relationship between RR, RIR and
the optimal treatment start time is similar for both the
simple and detailed models. This result is particularly
interesting because it emphasizes that (i) using a simple
model can highlight relationships in more detailed
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Figure 2. Effect of treatment start time on total attack rate (situation 1B). The vertical lines indicate the optimal treatment start
time t* for a large k (solid line), an intermediate k (dashed line) and a small k (dotted-dashed line). (a) The ﬁnal number of
susceptibles as a function of treatment start time for a large k (k ¼ 0.58; solid curve), an intermediate k (k ¼ 0.4; dashed curve)
and a small k (k ¼ 0.001; dotted-dashed curve). (b) The number of sensitive infections as a function of treatment start time, t.
The total attack rate is decreased by decreasing the number of sensitive infections at the treatment start time (I(t)) and by
decreasing the number of susceptibles at the treatment start time (S(t)) (equation (3.7)). As k increases, the effect of decreasing
I(t) becomes more important than decreasing S(t); therefore, t* decreases as k increases (from left to right, the order of the
vertical lines is solid, dashed and dot-dashed). (c) The number of susceptibles as a function of treatment start time. As k
increases, S(t*) increases. Also, the points S ¼ Smin are indicated by ‘star’ markers and coincide with S(t*). Parameters are
RI ¼ 1.6, RR ¼ 0.8RI and mI ¼ mR ¼ 1/3.3.
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Figure 3. Total attack ratio versus treatment level and number of susceptibles at treatment start time (normalized by S(t0)). The
white solid curves show the number of susceptibles at the optimal treatment start time provided a resistant epidemic occurs.
The white dashed horizontal lines indicate the number of susceptibles at the optimal treatment start time when the maximum
possible treatment level is very large (i.e. when umax is unbounded for the simple model and when fT ¼ 1 for the detailed
model). The white dashed horizontal lines in (a) and (b) were computed analytically; all other curves were computed numeri-
cally. It is important to emphasize that this ﬁgure was generated by assuming that an outbreak occurs. Indeed, for this speciﬁc
choice of parameters, electronic supplementary material, ﬁgure 3, illustrates that for umax . 0.25 and fT . 0.8 treating
immediately will prevent an outbreak and so treating immediately is optimal. (a) Figure produced using simple model. (b) Mag-
niﬁed version of (a). (c) Figure produced using detailed model. Parameters are RR ¼ 0.9RI, m1 ¼ m2 ¼ m3 ¼ 1/3.3, k ¼ 0.0066,
fr ¼ 0.002.
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quantity RIR is of general importance and not just an
artefact of our simple model.
4. DISCUSSION
Perhaps the most salient feature of previous analyses is
that the best treatment somehow balances the effects of
the sensitive and resistant epidemics. This trade-off,
which is very clearly explained in the discussion found
in Lipsitch et al. [9], is also highlighted in our model.
The difference is in the way this trade-off is resolved. In
Lipsitch et al. [9], this trade-off is used to explain why
an intermediate level of constant treatment is better
than a high level of constant treatment. Conversely, we
have shown that the optimal treatment balances this
trade-off by delaying the onset of treatment instead
of capping the maximum level of treatment. By allowing
the treatment strategy to vary in time, we have
shown that higher levels of treatment are always better,
provided they are started at the appropriate time. Fur-
thermore, when the maximum possible treatment level
is very large, our analysis shows that the optimal treat-
ment strategy is the one that switches from a sensitive
outbreak to a resistant outbreak precisely when the
number of susceptible hosts has decreased to the value
given by Smin.
We have examined two types of model, a simple model
that does not explicitly include the dynamics of the treat-
ment class and a more detailed model that does include
treatment dynamics. For the simple model, we showed,
using analytic calculations, that the optimal treatment
strategy is ‘off–on’ (i.e. delay treatment for a certain
amount of time—possibly no time—and then treat maxi-
mally for the remainder of the outbreak). It is important
to emphasize that for model (2.1) this off–on strategy is
indeed optimal in the sense that any other, more compli-
cated, strategy that involves intermediate levels of
treatment will not result in a lower attack ratio. Conver-
sely, for the more detailed model, we have only shown
(via numerical simulations) that an off–on strategy can
outperform a ‘constant’ strategy. Thus, although it
seems likely that the off–on strategy is optimal for the
more detailed model as well it remains an open problem
to explicitly prove that this is indeed the case. Further-
more, although an off–on strategy can be better than a
constant strategy, policy makers still face the ethical
dilemma of choosing between the rights of individuals
to receive treatment and the beneﬁt to the population of
delaying treatment.
Given the ethical problems associated with implement-
ing the optimal treatment strategy when it involves a delay,
it is useful to clearly delineate the conditions under which
implementing treatment immediately is actually optimal. It
is always optimal to start treatment immediately if one of
three conditions holds: (i) immediate treatment can pre-
vent an outbreak, (ii) the initial pool of susceptibles is
small (i.e. S(t0) , Smin for the simple model and S(t0) ,
Smin,c for the detailed model), or (iii) the rate of de novo
resistance is small (i.e. RIR . RR). Each of these three
situations have relevance to public health policy.
Condition (i) underscores that our focus has been to
minimize the total outbreak size, and so in this context
preventing an outbreak is the best possible outcome.
This outcome, however, may not be desirable if there is
a high probability of a second epidemic occurring at a
later time. For example, although treating immediately
at a very high level may minimize the total attack ratio,
this will result in S(tf) . SR . SI. As a result, the popu-
lation will be susceptible to future sensitive and resistant
outbreaks. Alternatively, if a treatment strategy is chosen
to ensure that a resistant epidemic occurs, then the ﬁnal
number of susceptibles will be small enough to prevent
future resistant outbreaks (and the severity of a possible
future sensitive outbreak will be signiﬁcantly decreased).
Antia et al. [26] discusses these issues in the context of
a single-strain epidemic. Interestingly, if delay is optimal,
then, up to a point, increasing umax will increase the opti-
mal amount of delay. However, if umax can be increased
sufﬁciently, then treating immediately will effectively pre-
vent the outbreak, and this then becomes the optimal
strategy. If this can occur, then policy makers will have
to balance the beneﬁts of treating immediately (and there-
fore preventing the current outbreak) with the beneﬁts of
delaying treatment (and perhaps minimizing the effects of
a second outbreak).
Condition (ii) highlights that the optimal treatment
strategy depends on the size of the target community.
Essentially, if a community is small enough, then treat-
ment should start immediately. This observation leads
to an interesting hypothesis for combined vaccination–
treatment policies. Namely, since vaccination decreases
the susceptible population, low vaccination levels make
it more likely that treatment should be delayed. This pro-
posed relationship is surprising since, naively, it seems
reasonable to expect that if fewer individuals are vac-
cinated, then it would be better to start treatment early
in order to reduce spread. Nevertheless, our results
suggest that this intuition is, in fact, incorrect.
Condition (iii) emphasizes that if the probability of
receiving treatment is low, then it is more likely that treat-
ment should start immediately. More concretely, by
expressing RIR as a linear combination of the two repro-
duction numbers RI and RR, we can rewrite RIR . RR as
RI
RR
.
1   kx
1   x
:
Therefore, if RI/RR . (1 2 kx)/(1 2 x), it is optimal to
start treatment immediately and if RI/RR   (1 2 kx)/
(1 2 x), then it may be best to delay treatment. For any
speciﬁc values of RI, RR and k, we see that as the pro-
bability of treating an infected individual, x, decreases,
it becomes more likely that starting treatment immedi-
ately is best. Intuitively, this guideline makes sense since
if treatment is unlikely to reach many infected individuals,
then it makes sense to start administering treatment as
soon as possible in order to reach more individuals.
Since multiple intervention measures are often used to
control a disease, an important next step is to consider a
model that includes other intervention measures, in
addition to treatment [4,5,7,10]. Some models similar
to our model that have included multi-intervention strat-
egies are the treatment–vaccination models in Ferguson
et al. [6] and Qiu & Feng [14], and the treatment-prophy-
laxis model in Lipsitch et al. [9]. Interestingly, a number
of studies that consider multi-intervention strategies also
exhibit optimal constant intervention levels. This suggests
1088 E. Hansen & T. Day Optimal treatment strategy and resistance
Proc. R. Soc. B (2011)that considering multi-intervention strategies that vary in
time may be very informative as well.
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